Oncology | Phase III Developments | FRANCE

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Sanofi, Regeneron Tout Libtayo's First Lung Cancer Win

Lead Product(s): Cemiplimab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Protocol-specified interim analysis conducted by the Independent Data Monitoring Committee demonstrated that patients treated with Libtayo monotherapy had a significant increase in overall survival.

OSE Immunotherapeutics SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Phase 3 Clinical Trial of Tedopi OSE Immunotherapeutics Announces Positive Top-Line Results

Lead Product(s): OSE2101

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

Primary endpoint was met in the predefined Step-1 analysis of its Phase 3 clinical trial of investigational product Tedopi®, called Atalante 1, in HLA-A2 positive non-small cell lung cancer.

Ipsen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook

Lead Product(s): Fluorouracil,Leucovorin Calcium,Irinotecan

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

Ipsen will continue the development of palovarotene, conduct further assessment of the MOVE dataset,

AB Science SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer...

Lead Product(s): Masitinib,Docetaxel Trihydrate,Prednisone

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2020

Details:

Study AB12003 is a multicenter, randomized, double blind, placebo-controlled, 2-parallel group, Phase 3 study in metastatic castrate resistant prostate cancer eligible to chemotherapy.

Nanobiotix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update

Lead Product(s): Hafnium dioxide,Cisplatin,Pembrolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

NANOBIOTIX will continue to prioritize its registration pathway in the US and EU for the treatment of head and neck cancers, while also working to advance the Nanobiotix immuno-oncology program.

Find

Find Oncology Drugs in Phase III Clinical Development in FRANCE

France

A collaboration with SCORR Marketing

Product Type

Companies

Sanofi

Sanofi, Regeneron Tout Libtayo's First Lung Cancer Win

OSE Immunotherapeutics SA

Phase 3 Clinical Trial of Tedopi OSE Immunotherapeutics Announces Positive Top-Line Results

Ipsen

Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook

AB Science SA

FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer...

Nanobiotix

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update